<u>Molecular Phenotypes</u> of Null Alleles in <u>Cells</u> (MorPhiC) Pre-Application Webinar

Ajay Pillai, Adam Felsenfeld, Colin Fletcher, & Riley Wilson National Human Genome Research Institute, Division of Genome Sciences September 2022



IH National Human Genom Research Institute The Forefront of Genomics[®]

Relevant Links

Current FOA: RFA-HG-22-019: Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase I: Data Analysis and Validation Centers grants.nih.gov/grants/guide/rfa-files/RFA-HG-22-019.html

Email Contact: morphicprogram@nih.gov

Webinar Link: genome.gov/event-calendar/MorPHiC-data-analysis-validation-centers-preapplication-webinar

Program Webpage: genome.gov/research-funding/Funded-Programs-Projects/Molecular-Phenotypes-of-Null-Alleles-in-Cells

FAQ: genome.gov/event-calendar/MorPhiC-pre-application-webinar/FAQ

2020 NHGRI Strategic Vision: genome.gov/2020SV

Past FOAs:

- RFA-HG-21-029: Data Production Research and Development Centers (UM1 Clinical trials not allowed)
- RFA-HG-21-031: Data Resource and Administrative Coordinating Center (U24 Clinical trials not allowed)





Overall Introduction (Adam Felsenfeld) (10 min)

RFA-HG-22-019: Data Analysis and Validation Centers (Ajay Pillai) (15 min)

Questions: 30 mins



To Note

- This call will be recorded and posted to the NHGRI MorPhiC Web pages.
- Your questions may be rendered into general FAQ's, with our answers, that will be linked to the MorPhiC Web pages.
- You do not have to identify yourself to ask a question.
- Please ask questions in the Q&A.



Part 1: Overview





5



MorPhiC

A C G C G T A C G

<u>Long-term</u> (more than 5 years): Develop a catalog of molecular and cellular phenotypes for null alleles in human, across the genome.

IDEAL:

- Consistent (i.e., standardized, well characterized assays)
- Null (or strong I.o.f.) alleles/KOs
- Informative M&C phenotypes; in multicellular systems
- "All" genes



- Lack of human KOs; there are mouse and other KOs, but not
- molecular/cellular phenotypes.
- Strong alleles are useful for interpreting other alleles (incl. noncoding).
- Resource for insight into pathways. Complement to cis-reg initiatives (e.g., IGVF)
- Collection of disease models
- Others...



Purpose of Phase 1

Understand main barriers to the "long term goal", by getting started at scale of ~1000 loci/5 years

- Criteria for selecting genes to learn lessons about doing this genome-wide
- Optimize making alleles
- Selecting cellular systems and assays for informativeness, generalizability, and scalability (tradeoffs!)
- Understand scale (costs, throughput)
- Raise and address challenges (pleiotropy, cell non-autonomy, compensation, variability)
- Understand/improve value of data (management, dissemination, quality, reproducibility, validation, variability, "use cases", interoperability, etc.) and feed back into data production/design

Phase 1: To inform feasibility, value, and design of Phase 2



F

MorPhiC Structure

Three components:

- Data production: 4 awards by Oct 2022
- Data resource and admin coordination: 1
 award by Oct 2022
- Data analysis and validation—this FOA



MorPhiC Overall: General advice (1)

- Cooperative Agreements
 - Substantial NHGRI program management
 - Collaborative tasks (e.g., sample prioritization, QC and data format discussions, data flow between the three component, etc.). Read the FOA *Terms & Conditions* for how this will be managed
 - Flexibility to set, and adjust, milestones (needed in a complex program)
 - There will be a "kick-off" meeting after grants are funded to establish consortium
- Letters of Intent– not required, but encouraged (Oct 1).



MorPhiC Overall: General advice (2)

- Always read the Review Criteria section of any FOA. This is what the reviewers will use to evaluate.
- Please read the instructions to applicants for the "Research Plan" sections.
- FOA's have a separate Resource Sharing section. *Will be considered in score.*
- Please read the section on "Review and Selection". It lists criteria that NHGRI may apply in selecting among well-scored applications.
- Read the Budget section (minimum time commitments; consortium meetings).
- Choose letters of support judiciously.



Ę

MorPhiC Overall: Diversity & Funding

NHGRI especially encourages applications from

- investigators from demographic groups or institutions that are generally underrepresented in genomic science
- new investigators
- experienced investigators who are new to genomic science
- investigators that have not previously participated in a NHGRI consortium or program



MorPhiC Overall: FAQ's

Please look out for these in the next month on the website <u>genome.gov/event-</u> <u>calendar/MorPhiC-pre-application-webinar/FAQ</u>

It will be updated.



Ę

Part 2: RFA HG-22-019

Data Analysis & Validation Centers



RFA HG-22-019: Outline

Primary goals

- data variability is controllable,
- data is useful to understand basic biological processes,
- data is interpretable for undertaking future hypothesisdriven science by the community.

Projects with high potential to illuminate strengths and weaknesses

Community utilization & feedback



RFA HG-22-019: Responsiveness

The FOA has a list of non-responsive criteria:

- Wet-lab data generation
- Do not propose to use MorPhiC data
- Do not address collaborations within Consortia
- Do not have a data sharing plan.



RFA HG-22-019: Challenges

Integrating data: between MorPhiC labs and 'related datasets'

- Identify & Correct technical bias
- Exptl design
- Effect of KO vs background changes
- Constructing representative GRNs
- Data integration: Multiome measurements

Sufficient metadata reflecting biology & data generation.

How can small labs use the data and models for downstream experiments?

RFA HG-22-019: Consortium responsibilities

How good/useful is the data?

Metadata and APIs and data access

Merits of common pipelines (leadership role)



RFA HG-22-019: Application & Review

Please follow instructions in the FOA about the Research Plan/Research Strategy sections.

- Budget: 350K direct cost/yr (max); 5 years
- Separate Data Sharing section & it is reviewed.
- Specific review criteria in the FOA.


Due Date: Nov 1, 2022



The MorPhiC: Data Production Centers (DPC)

- Each DPC proposes to analyze
 - their own data (single modality)
 - undertake some limited integrative analysis across their datasets to discover biology









F

Project 2









GT: 2D gastruloid; PI: Pancreatic Islet Organoids; NT: neuron/astrocyte/microglia tri-culture



F








F

The MorPhiC: Data Coordination Center

- The DRACC will be doing many things
 - A generic summary follows



Data Coordin ation





RFA HG-22-019

Questions?



27

Part 4: Tabular formatted Morphic Experimental Data



Project 1	Classes of Targeted Genes	Cellular Models	Types of Assays	Other General Scientific Questions to be Explored
Number of Knockouts	 ✓ 250 genes over 5 years ✓ 391 alleles over 5 years ✓ Main method: CRISPR-Cas9 KO 	Main workhorse ✓ differentiated cells: cellular system for KOLF2.1 (46;XY) large scale data generation	 ✓sc-transcriptomics at 4 different time points ✓sn-epigenetics ✓detailed high-resolution bulk proteomics & lipidomics (75 genes over 5 years): LC-MS and LC-MS/MS Main workshorse ✓ In biological triplicate assays (replication) 	second round of CRISPR-based editing to investigate: reversion
Classes of Targeted Genes	 ✓ gene selection criteria will focus on genes expressed at these early time points. ✓ Following classes will be included (and others based on Consortium discussion): developmental regulators; genes with overt transcriptional effects; others with no known transcriptional/chromatin regulation ✓ separate gene selection criteria for neuroectoderm lineage and extraembryonic lineage 	 ✓ iPSC's will subsequently be differentiated into two cell lineages: (1) the extra-embryonic, trophoblast and extra-embryonic mesoderm in monolayer cultures and (2 the neuroectodermal (early other cellular systems that will organoid cultures along the neuroectoderm lineage) 	✓ differentiation schemes will be temporally imaged to capture phenotypes &	 ✓ phenotyping efforts, in Phase I of MorPhiC, will focus on relatively early events in development ✓ compare KO strategies—editing biallelic premature termination codon, exon and gene deletion alleles for 24 genes assay based on transcription changes to identify reliable strategy for null allele generation

NHGRI

Classes of Targeted Genes

Cellular Models

Types of Assays

√ bulk RNA-Seg at 0, 6 & 48 hrs after null allele induction for 100 TFs √ bulk ATAC-Seq at 0, 6, & 48 hrs after null allele induction for 100 TFs ✓ IncuCyte live cell imaging platform to study viability, proliferation & mitotic defects after induction of null phenotype with auxin treatment

Other General Scientific Questions to be Explored

✓ Fitness & Stemness phenotype after null allele using FACS

✓ Differentiation propensity of 250 alleles into 3 germ layers. Mesoderm—cardiomyocytes, endoderm-hepatocyte-like cells, ectodermsensory neurons in a 10-day timeline. ✓ Cardiomyocytes: mature d30 cardiomyocytes will be studied for a limited number of KO alleles using (1) highthroughput Ca-transient measurement, and (2) microelectrode array measurement of field potential duration, beat rate etc.

genes Classes of √ 50 non-Targeted Genes

✓ 200 essential essential TFs

Other cellular systems that will be tested

Other assays that will be used in a √ Genotype √ Western targeted manner

✓ Compare ~50 clonal CRISPR KO with AIDmediated protein depletion (RNA and ATAC) \checkmark AID-knock-in strategy allows controlling the timing and the level of the target protein degradation and it is reversible (multiple downstream questions can be addressed).



2

Knockouts

inducible degron Number of technology (AID)

iPSC

 \checkmark 250 genes in

√ Main method: conditional null phenotype by using the Auxin Main workhorse cellular system for large scale data generation undertaken

selection of single cell clones (after transfection) a number of QC steps will be

√ Female

hiPSC line

√ After

Main workshorse assays



Cellular Models	Types of Assays	
		Other General Scientific Questions to be Explored
		с
	√ scRNA-seq (Perturb-	

Seq; 10x) √ Perturb-Seg on √ 96 curated (existing) hPSC lines; equal male, pooled clonal KO 5-10 female; emphasize diverse ancestry; healthy diverse hPSC lines \checkmark array individual lines in 96-well format, and then \checkmark (Custom scripts) for ✓ Phenotyping in diverse genetic pool the lines Perturb-Seq backgrounds \checkmark clonal KO lines for ~250 genes, select 3-5 diverse demultiplexing and ✓ Variability of differentiation ✓ Generate clonal KO lines for ~250 genes and representative hPSC lines, including RUES2 Main workhorse assignment of reads behavior (including proliferation related \checkmark generate "population KO" for 3-5 selected genes using cellular system for ✓ Differentiation (2D gastruloid, neuron-glial triissues in complex cell systems) and sgRNA. culture, and islet-like organoids) starting from 96 Number of all 96 curated hPSC lines Main workshorse large scale data \checkmark Some genes (due to pleiotropy) may ✓ Method: CRISPR-Cas9 based HDR need KO after differentiation Knockouts generation curated hPSC lines in a pooled format assays \checkmark 161 genes required for normal embryonic ✓ Improvements in power development in mice (distribution of genes with various calculations to determine # of cells mouse phenotypes)√ 50 genes linked to T2D and screened/sample (extensions into Alzheimer's disease based on human genetic studies pooled screens). Other cellular Other assays that Classes of Targeted \checkmark Set of +ve & -ve control genes to QC phenotype assays systems that will be will be used in a Genes tested ✓ Primary human islets targeted manner



